CoChat

Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome

Lin, Hung-Yu, Lu, Jian-He, Chuang, Shu-Mien, Chueh, Kuang-Shun, Juan, Tai-Jui, Liu, Yi-Chang, Juan, Yung-Shun · 2021 · Diagnostics
Cited by 51

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is defined as a chronic bladder disorder with suprapubic pain (pelvic pain) and pressure and/or discomfort related to bladder filling accompanied by lower urinary tract symptoms, such as urinary frequency and urgency without urinary tract infection (UTI) lasting for at least 6 weeks. IC/BPS presents significant bladder pain and frequency urgency symptoms with unknown etiology, and it is without a widely accepted standard in diagnosis. Patients’ pathological features through cystoscopy and histologic features of bladder biopsy determine the presence or absence of Hunner lesions. IC/PBS is categorized into Hunner (ulcerative) type IC/BPS (HIC/BPS) or non-Hunner (nonulcerative) type IC/BPS (NHIC/BPS). The pathophysiology of IC/BPS is composed of multiple possible factors, such as chronic inflammation, autoimmune disorders, neurogenic hyperactivity, urothelial defects, abnormal angiogenesis, oxidative stress, and exogenous urine substances, which play a crucial role in the pathophysiology of IC/BPS. Abnormal expressions of several urine and serum specimens, including growth factor, methylhistamine, glycoprotein, chemokine and cytokines, might be useful as biomarkers for IC/BPS diagnosis. Further studies to identify the key molecules in IC/BPS will help to improve the efficacy of treatment and identify biomarkers of the disease. In this review, we discuss the potential medical therapy and assessment of therapeutic outcome with urinary biomarkers for IC/BPS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics12010075

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 223

  1. Homma, 2020, Clinical guidelines for interstitial cystitis/bladder pain syndrome, Int. J. Urol. Off. J. Jpn. Urol. Assoc., 27, 578
  2. Hanno, 1999, The diagnosis of interstitial cystitis revisited: Lessons learned from the National Institutes of Health Interstitial Cystitis Database study, J. Urol., 161, 553, 10.1016/S0022-5347(01)61948-7 · DOI · Paper page
  3. Nickel, 2010, Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: A case control study, J. Urol., 183, 167, 10.1016/j.juro.2009.08.133 · DOI · Paper page
  4. Homma, 2009, Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome, Int. J. Urol., 16, 597, 10.1111/j.1442-2042.2009.02326.x · DOI · Paper page
  5. Abrams, 2002, The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society, Neurourol. Urodyn., 21, 167, 10.1002/nau.10052 · DOI · Paper page
  6. Malde, 2018, Guideline of guidelines: Bladder pain syndrome, BJU Int., 122, 729, 10.1111/bju.14399 · DOI · Paper page
  7. Erickson, 2005, Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis?, J. Urol., 173, 93, 10.1097/01.ju.0000146466.71311.ab · DOI
  8. Homma, 2016, Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015, Int. J. Urol., 23, 542, 10.1111/iju.13118 · DOI · Paper page
  9. Lee, 2018, Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome, Int. Urogynecol. J., 29, 1045, 10.1007/s00192-018-3574-x · DOI
  10. Ito, 2000, Interstitial cystitis in Japan, BJU Int., 86, 634, 10.1046/j.1464-410X.2000.00855.x · doi:10.1046/j.1464-410x.2000.00855.x
  11. Nickel, 1999, Research guidelines for chronic prostatitis: Consensus report from the first National Institutes of Health International Prostatitis Collaborative Network, Urology, 54, 229, 10.1016/S0090-4295(99)00205-8 · DOI · Paper page
  12. Clemens, 2015, Comparison of baseline urological symptoms in men and women in the MAPP research cohort, J. Urol., 193, 1554, 10.1016/j.juro.2014.11.016 · DOI · Paper page
  13. Marszalek, 2009, Chronic pelvic pain and lower urinary tract symptoms in both sexes: Analysis of 2749 participants of an urban health screening project, Eur. Urol., 55, 499, 10.1016/j.eururo.2008.03.073 · DOI
  14. Hosier, 2018, The X-Y factor: Females and males with urological chronic pelvic pain syndrome present distinct clinical phenotypes, Can. Urol. Assoc. J., 12, E270, 10.5489/cuaj.4798 · DOI
  15. Nordling, 2008, Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal, Eur. Urol., 53, 60, 10.1016/j.eururo.2007.09.019 · DOI · Paper page
  16. Engeler, 2018, EAU Guidelines on Chronic Pelvic Pain, Eur. Assoc. Urol., 18, 1
  17. Parsons, 1996, Cystoscopic changes in interstitial cystitis, Urology, 48, 289, 10.1016/S0090-4295(96)00179-3 · doi:10.1016/s0090-4295(96)00179-3
  18. Messing, 1997, Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study, Urology, 49, 81, 10.1016/S0090-4295(99)80336-7 · DOI
  19. Nigro, 1997, Associations among cystoscopic and urodynamic findings for women enrolled in the Interstitial Cystitis Data Base (ICDB) Study, Urology, 49, 86, 10.1016/S0090-4295(99)80337-9 · DOI
  20. Birder, 2013, Urothelial signaling, Physiol. Rev., 93, 653, 10.1152/physrev.00030.2012 · DOI · Paper page
  21. Maeda, D., Akiyama, Y., Morikawa, T., Kunita, A., Ota, Y., Katoh, H., Niimi, A., Nomiya, A., Ishikawa, S., and Goto, A. (2015). Hunner-Type (Classic) Interstitial Cystitis: A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation. PLoS ONE, 10. · DOI
  22. Richter, 2010, Bladder pain syndrome/interstitial cystitis in a Danish population: A study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis, BJU Int., 105, 660, 10.1111/j.1464-410X.2009.08847.x · doi:10.1111/j.1464-410x.2009.08847.x
  23. Arendsen, 2000, Interstitial cystitis: A review of immunological aspects of the aetiology and pathogenesis, with a hypothesis, BJU Int., 85, 995, 10.1046/j.1464-410x.2000.00646.x · DOI
  24. Saban, 2008, Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients, Am. J. Physiol. Ren. Physiol., 295, F1613, 10.1152/ajprenal.90344.2008 · DOI · Paper page
  25. Elbadawi, 1996, Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: New observations and their potential significance in pathogenesis, Urol. Int., 56, 137, 10.1159/000282832 · DOI · Paper page
  26. Tomaszewski, 2001, Biopsy features are associated with primary symptoms in interstitial cystitis: Results from the interstitial cystitis database study, Urology, 57, 67, 10.1016/S0090-4295(01)01166-9 · DOI · Paper page
  27. Gevaert, 2011, Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome, J. Cell Mol. Med., 15, 2586, 10.1111/j.1582-4934.2011.01262.x · doi:10.1111/j.1582-4934.2011.01262.x
  28. Altuntas, 2012, Autoimmunity to uroplakin II causes cystitis in mice: A novel model of interstitial cystitis, Eur. Urol., 61, 193, 10.1016/j.eururo.2011.06.028 · doi:10.1016/j.eururo.2011.06.028
  29. Theoharides, 2001, Mast cell involvement in interstitial cystitis: A review of human and experimental evidence, Urology, 57, 47, 10.1016/S0090-4295(01)01129-3 · DOI · Paper page
  30. Cao, 2005, Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor, J. Immunol., 174, 7665, 10.4049/jimmunol.174.12.7665 · DOI · Paper page
  31. Suzuki, 1999, Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P, J. Immunol., 163, 2410, 10.4049/jimmunol.163.5.2410 · DOI · Paper page
  32. Theoharides, 1995, Activation of bladder mast cells in interstitial cystitis: A light and electron microscopic study, J. Urol., 153, 629, 10.1016/S0022-5347(01)67669-9 · doi:10.1016/s0022-5347(01)67669-9
  33. Lundeberg, 1993, Interstitial cystitis: Correlation with nerve fibres, mast cells and histamine, Br. J. Urol., 71, 427, 10.1111/j.1464-410X.1993.tb15986.x · DOI · Paper page
  34. Sant, 2007, The mast cell in interstitial cystitis: Role in pathophysiology and pathogenesis, Urology, 69, 34, 10.1016/j.urology.2006.08.1109 · DOI · Paper page
  35. Tracey, 2008, Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacol. Ther., 117, 244, 10.1016/j.pharmthera.2007.10.001 · DOI · Paper page
  36. Jiang, Y.H., Peng, C.H., Liu, H.T., and Kuo, H.C. (2013). Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS ONE, 8. · DOI · Paper page
  37. Ogawa, 2010, CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis, J. Urol., 183, 1206, 10.1016/j.juro.2009.11.007 · DOI
  38. Felsen, 1994, Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis, J. Urol., 152, 355, 10.1016/S0022-5347(17)32739-8 · DOI
  39. Batler, 2002, Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha, J. Urol., 168, 819, 10.1016/S0022-5347(05)64750-7 · DOI
  40. Liu, 2008, RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model, J. Autoimmun., 30, 257, 10.1016/j.jaut.2007.10.005 · DOI
  41. Bosch, 2014, A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome, J. Urol., 191, 77, 10.1016/j.juro.2013.06.038 · DOI
  42. Bourne, 2008, A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: Exploring a new mechanism of action, BioDrugs, 22, 331, 10.2165/00063030-200822050-00005 · DOI
  43. Yoshimura, 2014, Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis, Int. J. Urol., 21, 18, 10.1111/iju.12308 · DOI
  44. Nicotra, 2012, Toll-like receptors in chronic pain, Exp. Neurol., 234, 316, 10.1016/j.expneurol.2011.09.038 · DOI · Paper page
  45. 2013, Highlights in basic autonomic neuroscience: Contribution of the urothelium to sensory mechanisms in the urinary bladder, Auton. Neurosci., 177, 67, 10.1016/j.autneu.2013.03.010 · doi:10.1016/j.autneu.2013.03.010
  46. Tian, 2015, Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats, Int. Neurourol. J., 19, 151, 10.5213/inj.2015.19.3.151 · doi:10.5213/inj.2015.19.3.151
  47. Hayashi, 2009, Bladder hyperactivity and increased excitability of bladder afferent neurons associated with reduced expression of Kv1.4 alpha-subunit in rats with cystitis, Am. J. Physiol. Regul. Integr. Comp. Physiol., 296, R1661, 10.1152/ajpregu.91054.2008 · DOI
  48. Mukerji, 2006, Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations, J. Urol., 176, 367, 10.1016/S0022-5347(06)00563-5 · doi:10.1016/s0022-5347(06)00563-5
  49. Homma, 2013, Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis, J. Urol., 190, 1925, 10.1016/j.juro.2013.05.049 · DOI
  50. Wada, 2015, Evaluation of prostaglandin E2 and E-series prostaglandin receptor in patients with interstitial cystitis, J. Urol., 193, 1987, 10.1016/j.juro.2015.01.010 · DOI
  51. Liu, 2009, Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment, BJU Int., 104, 1476, 10.1111/j.1464-410X.2009.08675.x · DOI
  52. Apostolidis, 2005, Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin, Urology, 65, 400, 10.1016/j.urology.2004.10.007 · DOI · Paper page
  53. Sun, 2004, Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis, J. Urol., 171, 448, 10.1097/01.ju.0000099660.46774.3c · DOI
  54. Yokoyama, 2004, Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity, J. Urol., 172, 596, 10.1097/01.ju.0000132769.71014.b5 · doi:10.1097/01.ju.0000132769.71014.b5
  55. Pumroy, 2020, Structural insights into the gating mechanisms of TRPV channels, Cell Calcium, 87, 102168, 10.1016/j.ceca.2020.102168 · DOI
  56. Frias, 2012, Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input, BJU Int., 110, E422, 10.1111/j.1464-410X.2012.11187.x · doi:10.1111/j.1464-410x.2012.11187.x
  57. Liu, 2014, Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome, Urol. Int., 92, 202, 10.1159/000355175 · doi:10.1159/000355175
  58. Chiu, B., Tai, H.C., Chung, S.D., and Birder, L.A. (2016). Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins, 8. · doi:10.3390/toxins8070201
  59. Wu, 2021, Emerging roles of the TRPV4 channel in bladder physiology and dysfunction, J. Physiol., 599, 39, 10.1113/JP279776 · DOI
  60. Everaerts, 2010, The vanilloid transient receptor potential channel TRPV4: From structure to disease, Prog. Biophys. Mol. Biol., 103, 2, 10.1016/j.pbiomolbio.2009.10.002 · DOI · Paper page
  61. Everaerts, 2010, Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis, Proc. Natl. Acad. Sci. USA, 107, 19084, 10.1073/pnas.1005333107 · DOI · Paper page
  62. Akiyama, 2019, Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review, Histol. Histopathol., 34, 25
  63. Hanno, 2010, Bladder pain syndrome international consultation on incontinence, Neurourol. Urodyn. Off. J. Int. Cont. Soc., 29, 191, 10.1002/nau.20847 · DOI · Paper page
  64. Shie, 2011, Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome, BJU Int., 108, E136, 10.1111/j.1464-410X.2010.09911.x · DOI · Paper page
  65. Liu, 2012, Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome, Urology, 80, 225.e13, 10.1016/j.urology.2012.01.047 · DOI
  66. D’Amico, R., Trovato Salinaro, A., Cordaro, M., Fusco, R., Impellizzeri, D., Interdonato, L., Scuto, M., Ontario, M.L., Crea, R., and Siracusa, R. (2021). Hidrox((R)) and Chronic Cystitis: Biochemical Evaluation of Inflammation, Oxidative Stress, and Pain. Antioxidants, 10. · DOI
  67. Hauser, 2008, Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis, J. Urol., 179, 764, 10.1016/j.juro.2007.09.022 · DOI
  68. Janssen, 2013, The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier, J. Urol., 189, 336, 10.1016/j.juro.2012.09.022 · doi:10.1016/j.juro.2012.09.022
  69. Tonelli, 2018, Transcriptional Regulation by Nrf2, Antioxid. Redox Signal., 29, 1727, 10.1089/ars.2017.7342 · DOI · Paper page
  70. Levonen, 2004, Cellular mechanisms of redox cell signalling: Role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products, Biochem. J., 378, 373, 10.1042/bj20031049 · DOI · Paper page
  71. Liu, 2019, The Bioprotective Effects of Polyphenols on Metabolic Syndrome against Oxidative Stress: Evidences and Perspectives, Oxid. Med. Cell Longev., 2019, 6713194, 10.1155/2019/6713194 · DOI · Paper page
  72. Ener, 2015, Evaluation of oxidative stress status and antioxidant capacity in patients with painful bladder syndrome/interstitial cystitis: Preliminary results of a randomised study, Int. Urol. Nephrol., 47, 1297, 10.1007/s11255-015-1021-1 · DOI
  73. Bozzatello, P., Garbarini, C., Rocca, P., and Bellino, S. (2021). Borderline Personality Disorder: Risk Factors and Early Detection. Diagnostics, 11. · DOI
  74. Nguyen, 2009, The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress, J. Biol. Chem., 284, 13291, 10.1074/jbc.R900010200 · DOI · Paper page
  75. Gee, 2010, p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress-induced angiogenesis, J. Cell. Physiol., 222, 120, 10.1002/jcp.21924 · DOI · Paper page
  76. Lee, 2011, Increased expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis, Urology, 78, 971.e11, 10.1016/j.urology.2011.05.050 · DOI
  77. Saban, 2015, Angiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insights, Transl. Urol., 4, 555
  78. Furuta, 2019, Angiogenesis in bladder tissues is strongly correlated with urinary frequency and bladder pain in patients with interstitial cystitis/bladder pain syndrome, Int. J. Urol., 26, 35, 10.1111/iju.13972 · doi:10.1111/iju.13972
  79. Akiyama, 2019, Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies, J. Urol., 202, 290, 10.1097/JU.0000000000000234 · doi:10.1097/ju.0000000000000234
  80. Peng, 2013, Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—Clinical results and immunohistochemistry analysis, Urology, 82, 1452.e1, 10.1016/j.urology.2013.09.003 · DOI
  81. Jhang, 2014, Elevated serum IgE may be associated with development of ketamine cystitis, J. Urol., 192, 1249, 10.1016/j.juro.2014.05.084 · DOI · Paper page
  82. Huang, 2014, Evaluation of the extent of ketamine-induced uropathy: The role of CT urography, Postgrad. Med. J., 90, 185, 10.1136/postgradmedj-2013-131776 · DOI · Paper page
  83. Huang, 2011, “Walking-stick ureters” in ketamine abuse, Kidney Int., 80, 895, 10.1038/ki.2011.242 · doi:10.1038/ki.2011.242
  84. Lee, 2013, Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: A comparison with non-ulcerative interstitial cystitis and controls, BJU Int., 112, 1156, 10.1111/bju.12256 · DOI · Paper page
  85. Anand, 2012, Mast cells: An expanding pathophysiological role from allergy to other disorders, Naunyn-Schmiedeberg’s Arch. Pharm., 385, 657, 10.1007/s00210-012-0757-8 · DOI
  86. Gamper, 2015, Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis?, J. Urol., 193, 1994, 10.1016/j.juro.2015.01.036 · DOI
  87. Akiyama, 2018, Digital quantitative analysis of mast cell infiltration in interstitial cystitis, Neurourol. Urodyn., 37, 650, 10.1002/nau.23365 · DOI
  88. Kim, 2017, Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion, Histopathology, 71, 415, 10.1111/his.13235 · DOI
  89. Theoharides, 2004, Critical role of mast cells in inflammatory diseases and the effect of acute stress, J. Neuroimmunol., 146, 1, 10.1016/j.jneuroim.2003.10.041 · DOI · Paper page
  90. Chung, 2011, Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder, Neurourol. Urodyn., 30, 417, 10.1002/nau.20938 · DOI
  91. Liu, 2009, Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection, Eur. Urol., 56, 700, 10.1016/j.eururo.2008.04.037 · doi:10.1016/j.eururo.2008.04.037
  92. Liu, 2008, Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder, J. Urol., 179, 2270, 10.1016/j.juro.2008.01.146 · DOI
  93. Liu, 2010, Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity, BJU Int., 106, 1681, 10.1111/j.1464-410X.2009.08851.x · doi:10.1111/j.1464-410x.2009.08851.x
  94. Lowe, 1997, Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis, Br. J. Urol., 79, 572, 10.1046/j.1464-410X.1997.00097.x · DOI · Paper page
  95. Kim, 2014, Voiding diary might serve as a useful tool to understand differences between bladder pain syndrome/interstitial cystitis and overactive bladder, Int. J. Urol., 21, 179, 10.1111/iju.12209 · DOI
  96. Charlanes, 2019, Diffusion-Weighted Magnetic Resonance Imaging: A New Tool for the Diagnosis of Bladder Pain Syndrome/Interstitial Cystitis, Urol. Int., 102, 109, 10.1159/000493507 · doi:10.1159/000493507
  97. Taidi, 2019, Purinergic P2X7 receptors as therapeutic targets in interstitial cystitis/bladder pain syndrome; key role of ATP signaling in inflammation, Bladder, 6, e38, 10.14440/bladder.2019.789 · DOI
  98. Doiron, 2016, Clinical Phenotyping Does Not Differentiate Hunner Lesion Subtype of Interstitial Cystitis/Bladder Pain Syndrome: A Relook at the Role of Cystoscopy, J. Urol., 196, 1136, 10.1016/j.juro.2016.04.067 · doi:10.1016/j.juro.2016.04.067
  99. Homma, 2019, Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome - clarification of definitions and relationships, Int. J. Urol., 26, 20, 10.1111/iju.13970 · DOI
  100. Logadottir, 2012, Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis, Scand. J. Urol. Nephrol., 46, 365, 10.3109/00365599.2012.689008 · doi:10.3109/00365599.2012.689008
  101. Lee, 2015, Correlation of cystoscopically confirmed periureterally located hunner lesion with vesicoureteral reflux: Preliminary study in patients with interstitial cystitis, AJR Am. J. Roentgenol., 204, W457, 10.2214/AJR.14.13108 · doi:10.2214/ajr.14.13108
  102. Colaco, 2014, Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome, J. Urol., 192, 1123, 10.1016/j.juro.2014.05.047 · DOI · Paper page
  103. Schachar, 2019, Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome, Int. Urogynecol. J., 30, 1863, 10.1007/s00192-019-04038-0 · DOI
  104. Mazeaud, 2019, Stratification of Patients With Interstitial Cystitis/Bladder Pain Syndrome According to the Anatomical Bladder Capacity, Urology, 123, 87, 10.1016/j.urology.2018.07.046 · DOI
  105. Sant, 1997, The interstitial cystitis symptom index and problem index, Urology, 49, 58, 10.1016/S0090-4295(99)80333-1 · DOI · Paper page
  106. Keller, 1994, Measurement of symptoms of interstitial cystitis. A pilot study, Urol. Clin. N. Am., 21, 67, 10.1016/S0094-0143(21)00593-0 · doi:10.1016/s0094-0143(21)00593-0
  107. Parsons, 2002, Increased prevalence of interstitial cystitis: Previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity, Urology, 60, 573, 10.1016/S0090-4295(02)01829-0 · DOI · Paper page
  108. Lubeck, 2001, Psychometric validation of the O’leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium, Urology, 57, 62, 10.1016/S0090-4295(01)01126-8 · DOI
  109. Wennevik, 2016, The Role of Glomerulations in Bladder Pain Syndrome: A Review, J. Urol., 195, 19, 10.1016/j.juro.2015.06.112 · DOI
  110. Liu, 2015, Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology, Low. Urin. Tract Symptoms, 7, 102, 10.1111/luts.12062 · doi:10.1111/luts.12062
  111. Said, 1989, Immunopathology of interstitial cystitis, Mod. Pathol., 2, 593
  112. Pang, 1995, Increased number of substance P positive nerve fibres in interstitial cystitis, Br. J. Urol., 75, 744, 10.1111/j.1464-410X.1995.tb07384.x · DOI · Paper page
  113. Yamada, 2000, Subtypes of bladder mast cells in interstitial cystitis, Int. J. Urol., 7, 292, 10.1046/j.1442-2042.2000.00197.x · DOI
  114. Charrua, 2021, Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis, Curr. Bladder Dysfunct. Rep., 16, 12, 10.1007/s11884-020-00626-9 · DOI
  115. Tyagi, 2012, Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis, J. Urol., 187, 2243, 10.1016/j.juro.2012.01.034 · DOI
  116. Southgate, 2007, Differentiation potential of urothelium from patients with benign bladder dysfunction, BJU Int., 99, 1506, 10.1111/j.1464-410X.2007.06795.x · DOI
  117. Zeng, 2007, Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis, J. Urol., 178, 1322, 10.1016/j.juro.2007.05.125 · DOI
  118. Bicer, 2015, Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model, Am. J. Physiol. Ren. Physiol., 308, F103, 10.1152/ajprenal.00202.2014 · DOI
  119. Gamper, 2013, Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C, Int. Urogynecol. J., 24, 2049, 10.1007/s00192-013-2112-0 · DOI
  120. Lee, 2006, Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE, Int. J. Urol., 13, 631, 10.1111/j.1442-2042.2006.01373.x · DOI
  121. Erickson, 2002, A comparison of multiple urine markers for interstitial cystitis, J. Urol., 167, 2461, 10.1016/S0022-5347(05)65005-7 · DOI · Paper page
  122. Sakthivel, 2008, CXCL10 blockade protects mice from cyclophosphamide-induced cystitis, J. Immune Based Vaccines, 6, 6, 10.1186/1476-8518-6-6 · DOI
  123. Lamale, 2006, Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis, Urology, 68, 702, 10.1016/j.urology.2006.04.033 · DOI
  124. Offiah, 2016, The Expression of Inflammatory Mediators in Bladder Pain Syndrome, Eur. Urol., 70, 283, 10.1016/j.eururo.2016.02.058 · doi:10.1016/j.eururo.2016.02.058
  125. Magalhaes, 2019, Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: A systematic review, Int. Urogynecol. J., 30, 1785, 10.1007/s00192-019-04075-9 · DOI
  126. Peters, 1999, Preliminary study on urinary cytokine levels in interstitial cystitis: Does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder?, Urology, 54, 450, 10.1016/S0090-4295(99)00162-4 · DOI
  127. Jiang, 2021, Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm, Sci. Rep., 11, 914, 10.1038/s41598-020-80131-5 · DOI
  128. Jhang, 2016, Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease, Int. Neurourol. J., 20, S95, 10.5213/inj.1632712.356 · DOI · Paper page
  129. Keay, 2001, Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor: Sensitive and specific urine markers for interstitial cystitis, Urology, 57, 104, 10.1016/S0090-4295(01)01028-7 · doi:10.1016/s0090-4295(01)01028-7
  130. Alleva, 2001, Psychosocial vs. “physical” stress situations in rodents and humans: Role of neurotrophins, Physiol. Behav., 73, 313, 10.1016/S0031-9384(01)00498-X · DOI
  131. Aloe, 1994, Nerve growth factor and autoimmune diseases, Autoimmunity, 19, 141, 10.3109/08916939409009542 · DOI
  132. Bonini, 1999, Nerve growth factor: An important molecule in allergic inflammation and tissue remodelling, Int. Arch. Allergy Immunol., 118, 159, 10.1159/000024055 · DOI · Paper page
  133. Okragly, 1999, Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients, J. Urol., 161, 438, 10.1016/S0022-5347(01)61915-3 · DOI · Paper page
  134. Jacobs, 2010, Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients, Can. J. Urol., 17, 4989
  135. Liu, 2008, Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment, Urology, 72, 104, 10.1016/j.urology.2008.01.069 · doi:10.1016/j.urology.2008.01.069
  136. Steers, 2006, Mechanisms of Disease: The role of nerve growth factor in the pathophysiology of bladder disorders, Nat. Clin. Pract. Urol., 3, 101, 10.1038/ncpuro0408 · DOI · Paper page
  137. Vizzard, 2000, Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction, Exp. Neurol., 161, 273, 10.1006/exnr.1999.7254 · DOI · Paper page
  138. Yoshimura, 1999, Bladder afferent pathway and spinal cord injury: Possible mechanisms inducing hyperreflexia of the urinary bladder, Prog. Neurobiol., 57, 583, 10.1016/S0301-0082(98)00070-7 · DOI · Paper page
  139. Schnegelsberg, 2010, Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function, Am. J. Physiol. Regul. Integr. Comp. Physiol., 298, R534, 10.1152/ajpregu.00367.2009 · DOI · Paper page
  140. Liu, H.T., and Kuo, H.C. (2012). Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS ONE, 7. · DOI
  141. Malykhina, A.P., Lei, Q., Erickson, C.S., Epstein, M.L., Saban, M.R., Davis, C.A., and Saban, R. (2012). VEGF induces sensory and motor peripheral plasticity, alters bladder function, and promotes visceral sensitivity. BMC Physiol., 12. · DOI
  142. Lai, 2017, Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study, BJU Int., 120, 576, 10.1111/bju.13924 · DOI
  143. Dagher, 2017, Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: Findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network, BJU Int., 120, 130, 10.1111/bju.13832 · DOI
  144. Kiuchi, 2009, Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: Its association with pain severity and glomerulations, BJU Int., 104, 826, 10.1111/j.1464-410X.2009.08467.x · doi:10.1111/j.1464-410x.2009.08467.x
  145. Furuta, 2018, Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder, Int. Urogynecol. J., 29, 961, 10.1007/s00192-017-3547-5 · DOI
  146. Tamaki, 2004, Possible mechanisms inducing glomerulations in interstitial cystitis: Relationship between endoscopic findings and expression of angiogenic growth factors, J. Urol., 172, 945, 10.1097/01.ju.0000135009.55905.cb · DOI · Paper page
  147. Shen, 2021, Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo, Sci. Rep., 11, 7558, 10.1038/s41598-021-87040-1 · DOI
  148. Feltis, 1987, Increased mast cells of the bladder in suspected cases of interstitial cystitis: A possible disease marker, J. Urol., 138, 42, 10.1016/S0022-5347(17)42981-8 · doi:10.1016/s0022-5347(17)42981-8
  149. Larsen, 1982, Mast cells in interstitial cystitis, Br. J. Urol., 54, 283, 10.1111/j.1464-410X.1982.tb06976.x · DOI · Paper page
  150. Cuevas, 1987, Adrenergic innervation of human middle cerebral artery. Ultrastructural observations, Surg. Neurol., 27, 113, 10.1016/0090-3019(87)90281-3 · doi:10.1016/0090-3019(87)90281-3
  151. Kastrup, 1983, Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis, Br. J. Urol., 55, 495, 10.1111/j.1464-410X.1983.tb03356.x · DOI · Paper page
  152. Aldenborg, 1986, Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis, Immunology, 58, 411
  153. Chuang, 2010, Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms, Urol. Sci., 21, 132, 10.1016/S1879-5226(10)60028-0 · doi:10.1016/s1879-5226(10)60028-0
  154. Sui, 2006, Characterization of the purinergic receptor subtype on guinea-pig suburothelial myofibroblasts, BJU Int., 97, 1327, 10.1111/j.1464-410X.2006.06200.x · doi:10.1111/j.1464-410x.2006.06200.x
  155. Sun, 2001, Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis, J. Urol., 166, 1951, 10.1016/S0022-5347(05)65726-6 · DOI · Paper page
  156. Birder, 2003, Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium, Am. J. Physiol. Ren. Physiol., 285, F423, 10.1152/ajprenal.00056.2003 · doi:10.1152/ajprenal.00056.2003
  157. Smith, 2005, Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A, Neurochem. Int., 47, 291, 10.1016/j.neuint.2005.04.021 · DOI
  158. Lawrence, 2010, Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers, J. Pharm. Exp., 334, 1080, 10.1124/jpet.110.169342 · DOI
  159. Sun, 2006, Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis, Am. J. Physiol. Cell Physiol., 290, C27, 10.1152/ajpcell.00552.2004 · DOI · Paper page
  160. Conrads, 2006, CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients, J. Biol. Chem., 281, 37836, 10.1074/jbc.M604581200 · doi:10.1074/jbc.m604581200
  161. Keay, 2004, An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide, Proc. Natl. Acad. Sci. USA, 101, 11803, 10.1073/pnas.0404509101 · DOI · Paper page
  162. Keay, 2001, Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis, Urology, 57, 9, 10.1016/S0090-4295(01)01127-X · doi:10.1016/s0090-4295(01)01127-x
  163. Kim, 2007, p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells, FEBS Lett., 581, 3795, 10.1016/j.febslet.2007.06.058 · DOI
  164. Keay, 2011, Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor, Chem. Biol. Drug Des., 77, 421, 10.1111/j.1747-0285.2011.01108.x · DOI
  165. Liebert, 2009, Interleukin-8 is essential for normal urothelial cell survival, Am. J. Physiol. Ren. Physiol., 297, F816, 10.1152/ajprenal.90733.2008 · DOI
  166. Huan, 2012, Scutellaria baicalensis alleviates cantharidin-induced rat hemorrhagic cystitis through inhibition of cyclooxygenase-2 overexpression, Molecules, 17, 6277, 10.3390/molecules17066277 · doi:10.3390/molecules17066277
  167. Kim, 2006, Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder, J. Urol., 175, 1773, 10.1016/S0022-5347(05)00992-4 · DOI · Paper page
  168. Galli, 2002, Analyzing the roles of mast cells and basophils in host defense and other biological responses, Int. J. Hematol., 75, 363, 10.1007/BF02982125 · DOI
  169. Fagerli, 1999, Intravesical capsaicin for the treatment of interstitial cystitis: A pilot study, Can. J. Urol., 6, 737
  170. Byrne, 1999, The urinary glycoprotein GP51 as a clinical marker for interstitial cystitis, J. Urol., 161, 1786, 10.1016/S0022-5347(05)68800-3 · DOI
  171. Shie, 2012, Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome, Urology, 79, 484.e7, 10.1016/j.urology.2011.09.049 · DOI · Paper page
  172. Bouchelouche, 2006, Interleukin-4 and 13 induce the expression and release of monocyte chemoattractant protein 1, interleukin-6 and stem cell factor from human detrusor smooth muscle cells: Synergy with interleukin-1beta and tumor necrosis factor-alpha, J. Urol., 175, 760, 10.1016/S0022-5347(05)00167-9 · doi:10.1016/s0022-5347(05)00167-9
  173. Dupont, 2001, Histological and neurotrophic changes triggered by varying models of bladder inflammation, J. Urol., 166, 1111, 10.1016/S0022-5347(05)65931-9 · DOI
  174. Kuo, 2010, Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms, Low. Urin. Tract Symptoms, 2, 88, 10.1111/j.1757-5672.2010.00065.x · DOI
  175. Zhang, C.O., Li, Z.L., and Kong, C.Z. (2005). APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis. BMC Urol., 5. · DOI
  176. Slobodov, 2004, Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis, J. Urol., 171, 1554, 10.1097/01.ju.0000118938.09119.a5 · DOI · Paper page
  177. Hurst, 2007, Bladder defense molecules, urothelial differentiation, urinary biomarkers, and interstitial cystitis, Urology, 69, 17, 10.1016/j.urology.2006.03.083 · DOI
  178. Parsons, 1990, Bladder surface glycosaminoglycans: An epithelial permeability barrier, J. Urol., 143, 139, 10.1016/S0022-5347(17)39897-X · DOI · Paper page
  179. Reitinger, 2013, Hyaluronan, a ready choice to fuel regeneration: A mini-review, Gerontology, 59, 71, 10.1159/000342200 · DOI
  180. Chen, 1999, Functions of hyaluronan in wound repair, Wound Repair Regen., 7, 79, 10.1046/j.1524-475X.1999.00079.x · DOI · Paper page
  181. Croce, 2001, Hyaluronan affects protein and collagen synthesis by in vitro human skin fibroblasts, Tissue Cell, 33, 326, 10.1054/tice.2001.0180 · DOI
  182. Meng, 2018, Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC), Low. Urin. Tract Symptoms, 10, 3, 10.1111/luts.12214 · DOI
  183. Daha, 2005, Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis?, Eur. Urol., 47, 393, 10.1016/j.eururo.2004.10.022 · doi:10.1016/j.eururo.2004.10.022
  184. Riedl, 2008, Hyaluronan treatment of interstitial cystitis/painful bladder syndrome, Int. Urogynecol. J. Pelvic Floor Dysfunct., 19, 717, 10.1007/s00192-007-0515-5 · doi:10.1007/s00192-007-0515-5
  185. Engelhardt, 2011, Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis, Int. Urogynecol. J., 22, 401, 10.1007/s00192-010-1294-y · doi:10.1007/s00192-010-1294-y
  186. Hung, 2014, Changes in sexual function of women with refractory interstitial cystitis/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution, J. Sex. Med., 11, 2256, 10.1111/jsm.12507 · doi:10.1111/jsm.12507
  187. Morales, 1996, Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis, J. Urol., 156, 45, 10.1016/S0022-5347(01)65933-0 · doi:10.1016/s0022-5347(01)65933-0
  188. Porru, 1997, Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid, Urol. Int., 59, 26, 10.1159/000283012 · doi:10.1159/000283012
  189. Kallestrup, 2005, Treatment of interstitial cystitis with Cystistat: A hyaluronic acid product, Scand. J. Urol. Nephrol., 39, 143, 10.1080/00365590410015876-1 · DOI
  190. Lai, 2013, Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: A comparative randomized assessment of different regimens, Int. J. Urol., 20, 203, 10.1111/j.1442-2042.2012.03135.x · DOI
  191. Kim, 2017, Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment, Investig. Clin. Urol., 58, 353, 10.4111/icu.2017.58.5.353 · DOI
  192. Jiang, Y.H., Liu, H.T., and Kuo, H.C. (2014). Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PLoS ONE, 9. · DOI
  193. Ozkidik, 2019, Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome, Cent. Eur. J. Urol., 72, 270
  194. Kuo, 2013, Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome, Int. J. Clin. Pract., 67, 427, 10.1111/ijcp.12113 · DOI · Paper page
  195. Wang, H.J., Yu, W.R., Ong, H.L., and Kuo, H.C. (2019). Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome. Toxins, 11. · doi:10.3390/toxins11110676
  196. Weiss, 2005, Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: Urodynamic outcome and patient satisfaction, Urology, 66, 82, 10.1016/j.urology.2005.01.036 · doi:10.1016/j.urology.2005.01.036
  197. Kuo, 2004, Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents, Urology, 63, 868, 10.1016/j.urology.2003.12.007 · doi:10.1016/j.urology.2003.12.007
  198. Apostolidis, 2005, Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J. Urol., 174, 977, 10.1097/01.ju.0000169481.42259.54 · doi:10.1097/01.ju.0000169481.42259.54
  199. Kuo, 2009, Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome, BJU Int., 104, 657, 10.1111/j.1464-410X.2009.08495.x · DOI · Paper page
  200. Pinto, 2013, Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis, J. Urol., 189, 548, 10.1016/j.juro.2012.09.027 · DOI

200 of 223 shown

Cited by

Metadata

Authors
Lin, H.-Y., Lu, J.-H., Chuang, S.-M., Chueh, K.-S., Juan, T.-J., Liu, Y.-C., & Juan, Y.-S.
Venue
Diagnostics
Publisher
MDPI AG
Published
2021-12-29
Volume
12
Issue
1
Pages
75
ISSN
2075-4418
Cited by
51
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.